Leontyev Danila, Neschadim Anton, Branch Donald R
Centre for Innovation, Canadian Blood Services, Toronto, Ontario, Canada; Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Division of Advanced Diagnostics, Infection and Immunity Group, Toronto General Research Institute, Toronto, Ontario, Canada.
Transfusion. 2014 Nov;54(11):2871-9. doi: 10.1111/trf.12680. Epub 2014 May 15.
Mouse models of human immune thrombocytopenia (ITP) have been used for years to investigate the mechanism of intravenous immunoglobulin (IVIG) to ameliorate ITP; however, how closely these experimental mouse models mirror the human autoimmune inflammatory disease is unclear. The aim of this study was to assess the cytokine profiles in experimental ITP with and without IVIG treatment.
We examined the production of 23 cytokines that included pro- and anti-inflammatory cytokines, in two different mouse strain models of ITP, BALB/c and C57BL/6J, with and without IVIG treatment.
In contrast to human ITP, in mouse models of ITP generated by passive transfer of an alloantibody we find no evidence of inflammatory disease even when ITP is robust, suggesting that while these models capture the innate response phase of the disease, they may not be capturing the adaptive mechanisms of autoimmune initiation of the disorder. Regardless of the mouse strain examined, interleukin (IL)-1α, -2, -6, -17, and -23; granulocyte-macrophage-colony-stimulating factor (GM-CSF); monocyte chemoattractant protein (MCP)-1; macrophage inflammatory protein (MIP)-1β; RANTES; tumor necrosis factor (TNF)-α; and interferon-γ remain at negligible levels after ITP induction. IVIG treatment in the absence of ITP induced significant levels of IL-4, -10, -11, -17, and -23; GM-CSF; MCP-1; and TNF-α in BALB/c mice, but only IL-11 was elevated in C57BL/6J mice. In response to IVIG treatment of ITP, both strains produced IL-4, -10, -11, and -23; GM-CSF; MCP-1; MIP-1β; and TNF-α; however, only BALB/c exhibited increased MCP-3 and RANTES. IL-11 levels were the highest of any cytokine after IVIG administration, given either alone or as treatment of ITP.
We conclude that mouse models for human ITP do not capture the full range of autoimmune inflammatory mechanisms of this disease. Furthermore, cytokine profiles differ in response to IVIG depending on the mouse strain used.
多年来,人类免疫性血小板减少症(ITP)的小鼠模型一直被用于研究静脉注射免疫球蛋白(IVIG)改善ITP的机制;然而,这些实验小鼠模型与人类自身免疫性炎症疾病的相似程度尚不清楚。本研究的目的是评估在有或无IVIG治疗的实验性ITP中的细胞因子谱。
我们在两种不同的ITP小鼠品系模型(BALB/c和C57BL/6J)中,检测了包括促炎和抗炎细胞因子在内的23种细胞因子的产生情况,这些模型有或无IVIG治疗。
与人类ITP不同,在通过同种异体抗体被动转移产生的ITP小鼠模型中,即使ITP严重,我们也未发现炎症疾病的证据,这表明虽然这些模型捕捉到了疾病的固有反应阶段,但它们可能未捕捉到该疾病自身免疫启动的适应性机制。无论检测的小鼠品系如何,在诱导ITP后,白细胞介素(IL)-1α、-2、-6、-17和-23;粒细胞-巨噬细胞集落刺激因子(GM-CSF);单核细胞趋化蛋白(MCP)-1;巨噬细胞炎性蛋白(MIP)-1β;调节激活正常T细胞表达和分泌的趋化因子(RANTES);肿瘤坏死因子(TNF)-α;以及干扰素-γ水平仍可忽略不计。在无ITP的情况下,IVIG治疗在BALB/c小鼠中诱导出显著水平的IL-4、-10、-11、-17和-23;GM-CSF;MCP-1;以及TNF-α,但在C57BL/6J小鼠中仅IL-11升高。针对ITP的IVIG治疗,两种品系均产生IL-4、-10、-11和-23;GM-CSF;MCP-1;MIP-1β;以及TNF-α;然而,只有BALB/c小鼠的MCP-3和RANTES增加。单独给予IVIG或作为ITP治疗后,IL-11水平是所有细胞因子中最高的。
我们得出结论,人类ITP的小鼠模型未捕捉到该疾病所有的自身免疫炎症机制。此外,根据所使用的小鼠品系不同,IVIG诱导的细胞因子谱也有所不同。